ATC Group: L04AC22 Spesolimab

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of L04AC22 in the ATC hierarchy

Level Code Title
1 L Antineoplastic and immunomodulating agents
2 L04 Immunosuppressants
3 L04A Immunosuppressants
4 L04AC Interleukin inhibitors
5 L04AC22

Active ingredients in L04AC22

Active Ingredient Description
Spesolimab

Spesolimab is a humanised antagonistic monoclonal immunoglobulin G1 (IgG1) antibody blocking human IL36R signalling. Binding of spesolimab to IL36R prevents the subsequent activation of IL36R by cognate ligands (IL36 α, β and γ) and downstream activation of pro-inflammatory pathways.

Related product monographs

Title Information Source Document Type  
SPEVIGO Concentrate for solution for infusion European Medicines Agency (EU) MPI, EU: SmPC

Medicines in this ATC group

United States (US)

France (FR)

Japan (JP)

Lithuania (LT)

Romania (RO)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.